Rapid development of stable transgene CHO cell lines by CRISPR/Cas9-mediated site-specific integration into C12orf35
Chinese hamster ovary (CHO) cells are the most widely used mammalian hosts for recombinant protein production. However, by conventional random integration strategy, development of a high-expressing and stable recombinant CHO cell line has always been a difficult task due to the heterogenic insertion and its caused requirement of multiple rounds of selection. Site-specific integration of transgenes into CHO hot spots is an ideal strategy to overcome these challenges since it can generate isogenic cell lines with consistent productivity and stability. In this study, we investigated three sites with potential high transcriptional activities: C12orf35, HPRT, and GRIK1, to determine the possible transcriptional hot spots in CHO cells, and further construct a reliable site-specific integration strategy to develop recombinant cell lines efficiently. Genes encoding representative proteins mCherry and anti-PD1 monoclonal antibody were targeted into these three loci respectively through CRISPR/Cas9 technology. Stable cell lines were generated successfully after a single round of selection. In comparison with a random integration control, all the targeted integration cell lines showed higher productivity, among which C12orf35 locus was the most advantageous in both productivity and cell line stability. Binding affinity and N-glycan analysis of the antibody revealed that all batches of product were of similar quality independent on integrated sites. Deep sequencing demonstrated that there was low level of off-target mutations caused by CRISPR/Cas9, but none of them contributed to the development process of transgene cell lines. Our results demonstrated the feasibility of C12orf35 as the target site for exogenous gene integration, and strongly suggested that C12orf35 targeted integration mediated by CRISPR/Cas9 is a reliable strategy for the rapid development of recombinant CHO cell lines.
KeywordsCHO Site-specific integration CRISPR/Cas9 Cell line development C12orf35
We would like to thank Dr. Xiangping Zhu, Yuan Gao, and Man Wang at Jecho Biopharmaceuticals Co., Ltd. in Tianjin, China, for professional help in quality analysis of the monoclonal antibodies.
This work was supported in part by the National Natural Science Foundation of China (No. 81273576, 81773621) and the Science & Technology Commission of Shanghai Municipality (No. 15431907000 and 17431904500).
Compliance with ethical standards
Conflict of interest
Authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals experiments.
- Ding K, Han L, Zong H, Chen J, Zhang B, Zhu J (2017) Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein. Appl Microbiol Biotechnol 101(5):1889–1898. https://doi.org/10.1007/s00253-016-7973-y CrossRefPubMedGoogle Scholar
- Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34(2):184–191. https://doi.org/10.1038/nbt.3437 CrossRefPubMedPubMedCentralGoogle Scholar
- He X, Tan C, Wang F, Wang Y, Zhou R, Cui D, You W, Zhao H, Ren J, Feng B (2016) Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res 44(9):e85. https://doi.org/10.1093/nar/gkw064 CrossRefPubMedPubMedCentralGoogle Scholar
- Hiller GW, Ovalle AM, Gagnon MP, Curran ML, Wang WG (2017) Cell-controlled hybrid perfusion fed-batch CHO cell process provides significant productivity improvement over conventional fed-batch cultures. Biotechnol Bioeng 114(7):1438–1447. https://doi.org/10.1002/bit.26259 CrossRefPubMedGoogle Scholar
- Kawabe Y, Komatsu S, Komatsu S, Murakami M, Ito A, Sakuma T, Nakamura T, Yamamoto T, Kamihira M (2017) Targeted knock-in of an scFv-Fc antibody gene into the hprt locus of Chinese hamster ovary cells using CRISPR/Cas9 and CRIS-PITCh systems. J Biosci Bioeng. https://doi.org/10.1016/j.jbiosc.2017.12.003
- Li S, Gao X, Peng R, Zhang S, Fu W, Zou F (2016) FISH-based analysis of clonally derived CHO cell populations reveals high probability for transgene integration in a terminal region of chromosome 1 (1q13). PLoS One 11(9):e0163893. https://doi.org/10.1371/journal.pone.0163893 CrossRefPubMedPubMedCentralGoogle Scholar
- Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31(9):833–838. https://doi.org/10.1038/nbt.2675 CrossRefPubMedPubMedCentralGoogle Scholar
- Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380–1389. https://doi.org/10.1016/j.cell.2013.08.021 CrossRefPubMedPubMedCentralGoogle Scholar
- Ritter A, Rauschert T, Oertli M, Piehlmaier D, Mantas P, Kuntzelmann G, Lageyre N, Brannetti B, Voedisch B, Geisse S, Jostock T, Laux H (2016) Disruption of the gene C12orf35 leads to increased productivities in recombinant CHO cell lines. Biotechnol Bioeng 113(11):2433–2442. https://doi.org/10.1002/bit.26009 CrossRefPubMedGoogle Scholar
- Sakuma T, Takenaga M, Kawabe Y, Nakamura T, Kamihira M, Yamamoto T (2015) Homologous recombination-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids. Int J Mol Sci 16(10):23849–23866. https://doi.org/10.3390/ijms161023849 CrossRefPubMedPubMedCentralGoogle Scholar
- Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2(9):846–856. https://doi.org/10.1158/2326-6066.CIR-14-0040 CrossRefPubMedGoogle Scholar
- Zhu J (2013) Update on production of recombinant therapeutic protein: transient gene expression. Smithers Rapra Technology Ltd.Google Scholar
- Zong H, Han L, Ding K, Wang J, Sun T, Zhang X, Cagliero C, Jiang H, Xie Y, Xu J, Zhang B, Zhu J (2017) Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via FUT8 knockout CHO-S cells. Eng Life Sci 17(7):801–808. https://doi.org/10.1002/elsc.201600255 CrossRefGoogle Scholar